Could Accelerate Diagnostics Inc Lose Strenght? Option Traders Don’t Think So

 Could Accelerate Diagnostics Inc Lose Strenght? Option Traders Don't Think So

In today’s session Accelerate Diagnostics Inc (AXDX) registered an unusually high (396) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious AXDX increase. With 396 contracts traded and 5174 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: AXDX161021C00025000 closed last at: $3.6 or 41.2% up. About 67,443 shares traded hands. Accelerate Diagnostics Inc (NASDAQ:AXDX) has risen 109.81% since March 4, 2016 and is uptrending. It has outperformed by 101.77% the S&P500.

Analysts await Accelerate Diagnostics Inc (NASDAQ:AXDX) to report earnings on November, 7. They expect $-0.33 EPS, down 32.00% or $0.08 from last year’s $-0.25 per share. After $-0.35 actual EPS reported by Accelerate Diagnostics Inc for the previous quarter, Wall Street now forecasts -5.71% EPS growth.

Accelerate Diagnostics Inc (NASDAQ:AXDX) Ratings Coverage

Out of 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $25 is the highest target while $17 is the lowest. The $25 average target is -7.48% below today’s ($27.02) stock price. Accelerate Diagnostics has been the topic of 5 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) earned “Overweight” rating by Piper Jaffray on Wednesday, December 16. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) earned “Neutral” rating by BTIG Research on Tuesday, August 25. JP Morgan initiated the stock with “Overweight” rating in Thursday, March 24 report. JP Morgan maintained the stock with “Overweight” rating in Tuesday, August 9 report. William Blair initiated Accelerate Diagnostics Inc (NASDAQ:AXDX) on Friday, January 8 with “Outperform” rating.

According to Zacks Investment Research, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado.”

Insitutional Activity: The institutional sentiment decreased to 1.14 in Q2 2016. Its down 0.64, from 1.78 in 2016Q1. The ratio is negative, as 8 funds sold all Accelerate Diagnostics Inc shares owned while 28 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 12.54 million shares or 1.89% less from 12.78 million shares in 2016Q1.
Rtw Ltd Llc reported 74,843 shares or 0.37% of all its holdings. Moreover, Millennium Mgmt Llc has 0% invested in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 25,307 shares. California State Teachers Retirement System holds 0% or 48,311 shares in its portfolio. Qs Investors Ltd Limited Liability Company owns 18 shares or 0% of their US portfolio. Fairfield Bush & holds 0.08% or 16,875 shares in its portfolio. Utd Advisers Limited Liability holds 10,715 shares or 0% of its portfolio. Obermeyer Wood Counsel Lllp holds 0.4% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 276,549 shares. State Street Corp has invested 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX). Bokf Na holds 0.01% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 11,384 shares. Legal & General Grp Incorporated Public Ltd last reported 0% of its portfolio in the stock. Coe Cap Mngmt Limited Liability Com accumulated 0% or 37,082 shares. Swiss Financial Bank holds 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 54,100 shares. Great West Life Assurance Com Can accumulated 0% or 2,080 shares. Art Limited Liability holds 0.01% or 16,867 shares in its portfolio. Deutsche Bancorp Ag, a Germany-based fund reported 67,284 shares.

Insider Transactions: Since May 13, 2016, the stock had 9 insider purchases, and 0 insider sales for $4.95 million net activity. SCHULER JACK W bought $191,831 worth of Accelerate Diagnostics Inc (NASDAQ:AXDX) on Tuesday, June 14.

Accelerate Diagnostics, Inc. is an in vitro diagnostics firm engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The company has a market cap of $1.39 billion. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. It currently has negative earnings. The Firm is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System , intended for the diagnosis of infectious pathogens.

AXDX Company Profile

Accelerate Diagnostics, Inc., incorporated on December 24, 2012, is an in vitro diagnostics firm engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Firm is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens.

More important recent Accelerate Diagnostics Inc (NASDAQ:AXDX) news were published by: Benzinga.com which released: “Cramer Likes Accelerate Diagnostics Inc” on April 03, 2016, also Globenewswire.com published article titled: “Accelerate Diagnostics Submits De Novo Request to FDA for Accelerate Pheno …”, Seekingalpha.com published: “Accelerate Diagnostics’ (AXDX) CEO Lawrence Mehren on Q2 2016 Results …” on August 08, 2016. More interesting news about Accelerate Diagnostics Inc (NASDAQ:AXDX) was released by: Globenewswire.com and their article: “Accelerate Diagnostics Reports Positive Results From Pilot Study of Its …” with publication date: December 02, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment